Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Xylem, Inc. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B), while Xylem, Inc. trades at $103.5 (market cap $23.99B). The key difference: Xylem, Inc. is far larger — about 3.3× Spyre Therapeutics Inc. Common Stock's market cap, and Xylem, Inc. pays a 1.67% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Xylem, Inc. for 51 Days on average.
| SYRE | XYL | |
|---|---|---|
Market Cap | $7.35B | $23.99B |
Volume | 1,624,631 | 2,429,384 |
Sector | Health | Industrials |
52-Week High | $108.92 | $152.95 |
52-Week Low | $22.18 | $100.92 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $6.35B | $25.77B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Xylem (XYL) trades at $102.54, down slightly by 0.05% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue has grown from $5.5B in 2022 to $9.04B in 2025, with net income margins improving to 10.59%. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, alongside a new CFO appointment.
The outlook is supported by steady revenue growth, margin expansion, and strategic acquisitions in water technology, though near-term sentiment is cautious due to technical weakness and China-related headwinds. Risks include execution of acquisitions and debt increase, but analyst consensus price target of $146.63 implies significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
